Recently, cardiovascular and antiviral drug developer Kejun Pharmaceutical completed over 300 million yuan in Series C financing. This round was led by WALVAX, with existing shareholder Tailong Capital's TaiKun Fund continuing to increase its stake, and several institutions including Qianhai Ark and Shenzhen Investment Venture Capital joining in.

It is understood that this round of financing will mainly be used to accelerate the global clinical development of multiple core and key pipelines. The collaboration between industrial capital and professional institutions marks a new fast track for the company's development.

Shanghai Kejun Pharmaceutical Technology Co., Ltd. was established in September 2018, with core team members coming from world-renowned multinational pharmaceutical companies, possessing rich experience in innovative drug research and development, clinical operations, and industrialization in multiple fields including cardiovascular, metabolism, and antiviral.

Currently, Kejun Pharmaceutical has built a globally leading "Aosheng" mRNA technology platform and "Puyu" prodrug technology platform, focusing on the research and development of innovative drugs with global competitiveness. Among its pipelines, there are several innovative drugs with independent global intellectual property rights and significant market potential.

Kejun Pharmaceutical's core product, Ifogrel (CG-0255), is a globally pioneering next-generation P2Y12 receptor inhibitor that combines intravenous and oral formulations. It employs an innovative thiol hydrolyzed prodrug design, enabling rapid onset of action (injection < 15 minutes, oral < 30 minutes) and completely overcoming the "clopidogrel resistance" issue present in about 58% of the Chinese population. Clinical data shows its antiplatelet efficacy is superior, with a 2mg dose achieving the same effect as 300mg of clopidogrel, and it has good safety, low individual variability, and low risk of drug-drug interactions. Its injectable formulation can fill a gap in the global stroke treatment field, while the oral formulation effectively addresses existing clinical treatment pain points. Currently, this product is advancing registration clinical research in the United States while simultaneously conducting Phase II clinical research in China.

In addition to the core product, several innovative drug pipelines with independent global intellectual property rights at Kejun Pharmaceutical have also made significant progress:

CG-0416 (weight loss and metabolic liver disease): A new generation of highly selective liver-targeted THR-β agonist has successfully entered Phase I clinical stage. This is another liver-targeted innovative drug developed based on the "Puyu" targeted prodrug technology platform, with differentiated advantages as it does not rely on central appetite suppression, significantly reducing liver fat and body weight while minimizing muscle loss, potentially providing a new all-oral solution for patients with obesity and metabolic diseases for "high-quality weight loss."

CG-1999 (functional cure for hepatitis B): The company has developed a therapeutic vaccine aimed at achieving functional cure for hepatitis B through the "Aosheng" mRNA technology platform, which can effectively induce specific immune responses to achieve effective suppression and clearance of the hepatitis B virus. In animal models, CG-1999 combined with siRNA/ASO can produce a clear synergistic effect, significantly accelerating the reduction of hepatitis B virus surface antigen HBsAg while effectively suppressing viral rebound after stopping siRNA/ASO treatment Based on solid technological strength, Kejun Pharmaceuticals will continue to increase investment in source innovation. With the funds from this round of financing, the company will accelerate the clinical development of core products and key pipelines while continuously promoting the iterative upgrades of its two core technology platforms. Additionally, it plans to further advance the preparation work for clinical trial applications (IND) of several highly promising preclinical candidate compounds (PCC), accelerating the entry of more high-quality, globally competitive innovative drugs into clinical trials, benefiting patients both domestically and internationally.

Dr. He Gongxin, founder and CEO of Kejun Pharmaceuticals, stated: "This round of financing will greatly assist us in accelerating the global clinical development process of our core products. Kejun Pharmaceuticals is committed to addressing major clinical needs such as cardiovascular and metabolic diseases through source innovation, bringing better treatment options to patients worldwide as soon as possible."